Navigation Links
Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
Date:11/6/2008

nd development reimbursements from Baxter of $66,000 and Roche of $214,000.

-- Research and development expenses for the third quarter of 2008 rose to $10.1 million, compared with $6.4 million for the third quarter of 2007, primarily due to an increase in research and development headcount, spending on the PEGPH20, insulin and dermatology clinical and pre-clinical programs, and production costs associated with the manufacturing scale-up of the rHuPH20 enzyme.

-- Selling, general and administrative expenses for the third quarter of 2008 were $3.5 million, compared with $2.8 million for the third quarter of 2007, reflecting increases in compensation expenses due to higher headcount.

-- Cash and cash equivalents totaled $72.5 million as of September 30, 2008, compared with $97.7 million as of December 31, 2007.

Conference Call

Halozyme management will host a conference call and webcast today to discuss these topics beginning at 1:30 p.m. PST (4:30 p.m. EST). To participate via telephone, please call 888-256-9044 for domestic callers or 706-643-5585 for international callers. The conference ID # is 71335335. A telephone replay will be available for 48 hours by dialing 800-642-1687 for domestic callers or 706-645-9291 for international callers. The conference call will be broadcast live over the Internet at http://www.halozyme.com and the replay will be available on the company's website for 30 days.

Upcoming Corporate Presentations

Halozyme management is scheduled to present at the following investment conferences:

-- Lazard Capital Markets 5th Annual Healthcare Conference to be held at the St. Regis Hotel in New York on Tuesday, November 18, 2008 at 2:40 p.m. EST (11:40 a.m. PST)

-- Piper Jaffray 20th Annual health Care Conference to be held at the New York Palace Hotel in New York on Wednesday, December 3, 2008 at 3:30 p.m. EST (12:30 p.m. PST).

Ab
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
2. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics to Host Research Day for Investors and Analysts
5. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  Health Enhancement Products, Inc. (OTCQB: HEPI), a ... bioactive compounds and metabolic processes, is pleased to announce the ... directors. Ms. Nola E. Masterson , a ... board effective September 17, 2014. "We,re very ... our board," states Andrew Dahl , President and CEO. ...
(Date:9/18/2014)... -- Research and Markets has announced the ... Industry Report, 2014-2017" report to their offering. ... can differentiate into specialized cells and can divide (through ... can be applied to treatment of cardiovascular diseases, leukemia ... damage or lesion of liver, kidney and other parenchymal ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Leatherwood ... FM-4910 listed material, to stay competitive in the ... These high-performance materials ultimately impact product quality and ... and owner. , Established in 1980 in Lewisville, ... as many fabricators have left the business. Much ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. ... of previously announced concurrent but separate underwritten offerings of ... to the public of $2.00 per share, for expected ... its Series A Convertible Preferred Stock at a price ... gross proceeds of $20 million. Each share of Series ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... Inc.,(NYSE: SNN , LSE: SN) Orthopaedic Reconstruction ... instrumentation for use in total,knee replacement surgery. The VISIONAIRE ... x-rays to create custom surgical instrumentation for,use with the ... , By using instruments designed ...
... EAST LONGMEADOW, Mass., Feb. 23 Texcel Medical, ... development and contract manufacturing company, has announced ... CEO.Smith will oversee all functions at Texcel ... by providing the manufacturing infrastructure and expertise they ...
... Affairs Company LLC,(TMAC(R)), the leading provider of outsourced ... expansion of its medical,communications division. , ... demand for clinician-staffed,project-based medical information and medical meeting ... its Medical Communications division to,better meet these needs. ...
Cached Biology Technology:Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 2Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 3Texcel Medical Appoints Barry Smith as President, CEO 2The Medical Affairs Company Expands Its Medical Communications Division 2
(Date:9/18/2014)... cycles of carbon and nitrogen comprise all spheres ... environmental systems have caused imbalances and perturbations that ... (GHGs). Increased GHGs result in climate changes which ... oceans and the atmosphere. Understanding these feedback mechanisms ... of environmental science during the past three decades. ...
(Date:9/18/2014)... camouflage: you don,t just blend in, the background shows ... as you might think. Kathryn Feller, from the University ... life stages of many marine species are transparent. However, ... creatures cannot make transparent. Feller explains that the animals ... unit with an opaque pigment to prevent light leaking ...
(Date:9/17/2014)... of the Santa Ana Wildfire Threat Index a ... the powerful, hot, dry Santa Ana wind, which can ... introduced Sept. 17 by the U.S. Forest Service, in ... , The index includes four classification levels ranging from ... fire agencies and other emergency responders, the media and ...
Breaking Biology News(10 mins):Greenhouse gas research enters a new era 2Transparent larvae hide opaque eyes behind reflections 2UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2
... a plant genetics and developmental biology expert at the ... of 15 five-year, $5 million grants for fundamental plant ... the Howard Hughes Medical Institute (HHMI) and the Gordon ... W. Beadle Professor of Biology at Caltech, is an ...
... the Bourns College of Engineering at the University of California, ... EPA to develop a system could cut electricity bills up ... attic to operate a clothes dryer. The students are ... a 30-home zero net energy, urban agriculture focused community planned ...
... RIDGE, Tenn., June 15, 2011 A first of ... Department of Energy,s Oak Ridge National Laboratory is providing ... biofuels. , Lignin, a major component of plant cell ... the production of cellulosic ethanol. The exact shape and ...
Cached Biology News:Caltech scientist awarded $5 million grant for plant research 2Turning hot air into energy savings 2Turning hot air into energy savings 3ORNL neutrons, simulations reveal details of bioenergy barrier 2
Rabbit polyclonal to hnRNP-U...
... DNA Ligase catalyzes the formation of a ... termini in nicked duplex DNA molecules or ... a complementary strand at 45 - 65?. ... at much higher temperatures than conventional DNA ...
RABBIT ANTI RHEB (IN) Immunogen: A 15 amino acid peptide located in the central region of human Rheb....
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
Biology Products: